HUMA
#3678
Humacyte, Inc. - Common Stock
0.6 5 USD
-0.06%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
-5.80%
Monthly Change
0.00%
6 month change
-39.81%
Year Change
-56.67%
Previous Close
0.6 9
Open
0.6 5
Low
0.6 5
High
0.6 5
Volume
40
Financials
- Market Capitalization 180.57 M
- Employee 184
- Founded 2004
- CEO Laura Niklason
- Website www.humacyte.com
- Headquarter Delaware, United States
- FIGI BBG00XPPT7S7
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-3.69
Price to sales ratio
74.54
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 3656 |  KRRO Korro Bio, Inc. - Common Stock | 12.91 USD | -2.64% | -2.05% | +25.83% | -66.81% | 190.11 M USD | ||
| 3673 |  MOLN Molecular Partners AG - American Depositary Shares | 4.50 USD | -3.23% | +4.65% | +5.88% | +16.28% | 181.69 M USD | ||
| 3695 |  SPRB Spruce Biosciences, Inc. - Common Stock | 60.78 USD | -3.98% | +13.61% | +44.75% | +452.55% | 174.68 M USD | ||
| 3697 |  ADAG Adagene Inc - ADS, each representing 1.25 | 3.68 USD | -5.64% | -7.77% | -1.60% | +73.58% | 174.38 M USD |
Frequently asked questions about Humacyte, Inc. Common Stock
What is the Humacyte, Inc. Common Stock stock price today?
The current price of Humacyte, Inc. Common Stock (HUMA) is 0.65. Over the past 24 hours, the stock has changed by -5.80%. Follow the HUMA chart for real-time price dynamics.
What is the stock ticker of Humacyte, Inc. Common Stock?
Humacyte, Inc. Common Stock trades under the ticker HUMA. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Humacyte, Inc. Common Stock stock going up?
HUMA has changed by -4.41% over the last week, 0.00% over the last month, and -56.67% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Humacyte, Inc. Common Stock?
Humacyte, Inc. Common Stock currently has a market capitalization of 180.57 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Humacyte, Inc. Common Stock earnings last quarter?
Last quarter, Humacyte, Inc. Common Stock reported earnings of -0.16 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Humacyte, Inc. Common Stock revenue for the last quarter?
Humacyte, Inc. Common Stock reported quarterly revenue of 406 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Humacyte, Inc. Common Stock net income for the last quarter?
Humacyte, Inc. Common Stock reported net income of -36.8 M for the last quarter. The previous quarter showed -17.62 M, which means net income changed by -108.88%.
How many employees does Humacyte, Inc. Common Stock have?
As of the latest available data, Humacyte, Inc. Common Stock has 184 employees. Workforce size can provide additional context about the company's scale and operations.
What is Humacyte, Inc. Common Stock EBITDA?
Humacyte, Inc. Common Stock EBITDA is -24.91 M, and its EBITDA margin is -6 135.96%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Humacyte, Inc. Common Stock stock?
You can buy Humacyte, Inc. Common Stock (HUMA) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Humacyte, Inc. Common Stock stock?
Investing in Humacyte, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the HUMA chart and related analysis on metatrader.com as part of your research.